ATE450499T1 - Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten - Google Patents
Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivatenInfo
- Publication number
- ATE450499T1 ATE450499T1 AT03791043T AT03791043T ATE450499T1 AT E450499 T1 ATE450499 T1 AT E450499T1 AT 03791043 T AT03791043 T AT 03791043T AT 03791043 T AT03791043 T AT 03791043T AT E450499 T1 ATE450499 T1 AT E450499T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- sub
- independently
- compounds
- treatment
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 3
- 108090000790 Enzymes Proteins 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical class N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000002148 esters Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 101000624947 Homo sapiens Nesprin-1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100023306 Nesprin-1 Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 abstract 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical group ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 abstract 1
- 229960004961 mechlorethamine Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0220319.8A GB0220319D0 (en) | 2002-09-02 | 2002-09-02 | Enzyme activated self-immolative nitrogen mustard drugs |
| PCT/GB2003/003736 WO2004020400A1 (en) | 2002-09-02 | 2003-09-01 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE450499T1 true ATE450499T1 (de) | 2009-12-15 |
Family
ID=9943326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03791043T ATE450499T1 (de) | 2002-09-02 | 2003-09-01 | Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7235585B2 (de) |
| EP (1) | EP1534670B1 (de) |
| AT (1) | ATE450499T1 (de) |
| AU (1) | AU2003259382A1 (de) |
| CA (1) | CA2496470A1 (de) |
| DE (1) | DE60330356D1 (de) |
| GB (1) | GB0220319D0 (de) |
| WO (1) | WO2004020400A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX2010007419A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| HK1198443A1 (en) | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| AU2013337717B2 (en) | 2012-11-01 | 2018-10-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| MX382033B (es) | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
| MX2020012674A (es) * | 2018-05-29 | 2021-02-09 | Bristol Myers Squibb Co | Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8820850D0 (en) | 1988-09-05 | 1988-10-05 | Cancer Res Campaign Tech | Improvements relating to pro-drugs |
| GB8920011D0 (en) | 1989-09-05 | 1989-10-18 | Mann J | New route of synthesis for tertiary butyl esters |
| GB9308957D0 (en) | 1993-04-30 | 1993-06-16 | Cancer Res Campaign Tech | Novel produgs |
| ATE361759T1 (de) | 1993-07-15 | 2007-06-15 | Cancer Res Campaign Tech | Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können |
| GB9315494D0 (en) | 1993-07-27 | 1993-09-08 | Springer Caroline | Improvements relating to prodrugs |
| GB9415167D0 (en) | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
| GB9501052D0 (en) * | 1995-01-19 | 1995-03-08 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| GB9601640D0 (en) | 1996-01-26 | 1996-03-27 | Cancer Res Campaign Tech | Ligand directed enzyme prodrug therapy |
| GB9907414D0 (en) * | 1999-03-31 | 1999-05-26 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| GB0102239D0 (en) | 2001-01-29 | 2001-03-14 | Cancer Res Ventures Ltd | Methods of chemical synthisis |
-
2002
- 2002-09-02 GB GBGB0220319.8A patent/GB0220319D0/en not_active Ceased
-
2003
- 2003-09-01 WO PCT/GB2003/003736 patent/WO2004020400A1/en not_active Ceased
- 2003-09-01 CA CA002496470A patent/CA2496470A1/en not_active Abandoned
- 2003-09-01 AT AT03791043T patent/ATE450499T1/de not_active IP Right Cessation
- 2003-09-01 DE DE60330356T patent/DE60330356D1/de not_active Expired - Lifetime
- 2003-09-01 AU AU2003259382A patent/AU2003259382A1/en not_active Abandoned
- 2003-09-01 EP EP03791043A patent/EP1534670B1/de not_active Expired - Lifetime
- 2003-09-01 US US10/526,173 patent/US7235585B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20060069154A1 (en) | 2006-03-30 |
| GB0220319D0 (en) | 2002-10-09 |
| AU2003259382A1 (en) | 2004-03-19 |
| DE60330356D1 (en) | 2010-01-14 |
| CA2496470A1 (en) | 2004-03-11 |
| WO2004020400A1 (en) | 2004-03-11 |
| US7235585B2 (en) | 2007-06-26 |
| EP1534670A1 (de) | 2005-06-01 |
| EP1534670B1 (de) | 2009-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE450499T1 (de) | Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten | |
| ATE495155T1 (de) | Heterocyclische inhibitoren von mek | |
| MXPA04002167A (es) | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
| MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| BR0306292A (pt) | Composto de éster e uso medicinal do mesmo | |
| NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
| ATE484514T1 (de) | Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs | |
| DE60235299D1 (de) | 4-aryl substituierte chinole und analoga als therapeutische wirkstoffe | |
| WO2004066952A3 (en) | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | |
| IL151167A0 (en) | Pyrrolopyridazine derivatives and pharmaceutical compositions containing the same | |
| EP1806136A4 (de) | Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie | |
| WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
| IL169577A0 (en) | Oligosaccharide derivatives and pharmaceutical compostions containing the same | |
| DE60305520D1 (de) | 2" oxo-voruscharin und derivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |